Q1 EPS Estimates for Exact Sciences Lifted by Analyst

Exact Sciences Co. (NASDAQ:EXAS) – Research analysts at Leerink Partnrs raised their Q1 2025 earnings per share (EPS) estimates for shares of Exact Sciences in a report released on Thursday, February 20th. Leerink Partnrs analyst P. Souda now forecasts that the medical research company will post earnings per share of ($0.06) for the quarter, up from their prior estimate of ($0.10). The consensus estimate for Exact Sciences’ current full-year earnings is ($0.58) per share. Leerink Partnrs also issued estimates for Exact Sciences’ Q2 2025 earnings at $0.03 EPS, Q1 2026 earnings at $0.10 EPS, Q3 2026 earnings at $0.26 EPS and Q4 2026 earnings at $0.34 EPS.

Exact Sciences (NASDAQ:EXAS) last announced its earnings results on Wednesday, February 19th. The medical research company reported ($0.06) earnings per share for the quarter, topping the consensus estimate of ($0.29) by $0.23. Exact Sciences had a negative return on equity of 5.29% and a negative net margin of 37.29%. The firm had revenue of $713.42 million for the quarter, compared to the consensus estimate of $701.45 million.

EXAS has been the topic of several other research reports. William Blair reiterated an “outperform” rating on shares of Exact Sciences in a research note on Thursday, February 20th. Bank of America dropped their price target on Exact Sciences from $72.00 to $65.00 and set a “buy” rating on the stock in a research note on Thursday, February 20th. Citigroup dropped their price target on Exact Sciences from $80.00 to $75.00 and set a “buy” rating on the stock in a research note on Wednesday, November 6th. The Goldman Sachs Group dropped their price target on Exact Sciences from $75.00 to $65.00 and set a “buy” rating on the stock in a research note on Wednesday, November 6th. Finally, Jefferies Financial Group boosted their price objective on Exact Sciences from $84.00 to $85.00 and gave the company a “buy” rating in a report on Wednesday, November 6th. One analyst has rated the stock with a hold rating and eighteen have assigned a buy rating to the company. According to data from MarketBeat, Exact Sciences currently has an average rating of “Moderate Buy” and an average price target of $72.24.

Exact Sciences Stock Up 4.1 %

Shares of EXAS stock opened at $51.28 on Monday. Exact Sciences has a 1-year low of $40.62 and a 1-year high of $79.62. The stock’s fifty day moving average price is $54.72 and its 200 day moving average price is $60.00. The company has a debt-to-equity ratio of 0.97, a current ratio of 2.15 and a quick ratio of 1.93. The company has a market cap of $9.53 billion, a price-to-earnings ratio of -9.21 and a beta of 1.24.

Institutional Investors Weigh In On Exact Sciences

Institutional investors have recently modified their holdings of the company. Huntington National Bank boosted its stake in shares of Exact Sciences by 838.1% during the 3rd quarter. Huntington National Bank now owns 394 shares of the medical research company’s stock worth $27,000 after acquiring an additional 352 shares in the last quarter. RPg Family Wealth Advisory LLC purchased a new stake in Exact Sciences in the 3rd quarter valued at approximately $34,000. Capital Performance Advisors LLP purchased a new stake in Exact Sciences in the 3rd quarter valued at approximately $35,000. Vestor Capital LLC purchased a new stake in Exact Sciences in the 3rd quarter valued at approximately $46,000. Finally, Asset Planning Inc purchased a new stake in Exact Sciences in the 4th quarter valued at approximately $40,000. Hedge funds and other institutional investors own 88.82% of the company’s stock.

About Exact Sciences

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.